JointHealth™ express July 18, 2016
Reminder: Let BC PharmaCare hear "Your Voice" on secukinumab
BC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis
Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health's PharmaCare program. You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.
The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Wednesday, July 20 so that we may submit the questionnaire in time for the deadline.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
Reminder: Let BC PharmaCare hear "Your Voice" on secukinumab
BC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis
Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health's PharmaCare program. You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.
The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Wednesday, July 20 so that we may submit the questionnaire in time for the deadline.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for secukinumab for ankylosing spondylitis: click here
- To view the information sheet for secukinumab for psoriatic arthritis: click here
- For the Patient Questionnaire: Please click on ankylosing spondylitis or psoriatic arthritis
- For the Caregiver Questionnaire: Please click on ankylosing spondylitis or psoriatic arthritis
- For the Patient Group Questionnaire: Please click on ankylosing spondylitis or psoriatic arthritis (Patient groups are required to register their name with the Ministry of Health before making their submission.)
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.